Calendario›ARVN›ARV-806
ARV-806
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Ensayo de ARVINAS, INC. en Mutacion KRAS G12D · Cancer solido avanzado.
- Fase
- Fase 1/2
- Estado
- En marcha, sin reclutar
- Participantes
- 76
- Centros
- 14
- Fin del objetivo primario
- nov 2026
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en may 2025.
Qué mide
Parte A (Fase 1): Numero de toxicidades limitantes de dosis (DLT) de ARV-806 (28 days from first ARV-806 administration) (del registro, en inglés)
Qué se prueba
El estudio evalua la seguridad y posible actividad antitumoral de ARV-806 en adultos con cancer avanzado que presentan una mutacion especifica de KRAS.
Lo que dice el documentoThis is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
Traducción automática (claude-sonnet-5), con la cita comprobada contra el documento y revisada por una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-806. Researchers think that ARV-806 can work by breaking down a specific protein with a mutation that is present in some tumors, which might help prevent or slow tumors from growing. This will be the first time ARV-806 will be used in people. The investigational drug will be given through a vein. This is called intravenous (IV) infusion. This study will include 2 parts: In Part A (Phase 1), different small groups of participants will receive lower to higher doses of ARV-806. Adults with advanced cancers having a specific KRAS mutation will be included. In Part B (Phase 2), participants will be assigned to receive one of up to 2 dose levels decided by the information from Part A. Part B will include participants with advanced pancreatic ductal cancer having a specific KRAS mutation.
Más ensayos de ARVN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| ARV-393 | Fase 1 | Reclutando pacientes | mar 2028 (prevista) |
| ARV-6723 | Fase 1/2 | Reclutando pacientes | mar 2031 (prevista) |
| Vepdegestrant · mBC | Fase 1/2 | Completado | sep 2024 (real) |
| ARV-471 | Fase 2 | Completado | jul 2024 (real) |
| TACTIVE-E | Fase 1 | Completado | jul 2024 (real) |
| Bavdegalutamide | Fase 1 | Completado | jul 2024 (real) |
Todos los de ARVN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07023731), actualizada en sep 2026.